- Home
- CTO vs AUTL Comparison
CTO vs AUTL Comparison
Compare CTO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | AUTL |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.6M | 532.3M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CTO | AUTL |
|---|---|---|
| Price | $21.97 | $2.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $22.50 | $8.50 |
| AVG Volume (30 Days) | 333.1K | ★ 3.2M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | ★ 122.86 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $149,545,000.00 | $10,120,000.00 |
| Revenue This Year | $7.63 | $80.32 |
| Revenue Next Year | $2.76 | $53.96 |
| P/E Ratio | $169.08 | ★ N/A |
| Revenue Growth | 20.10 | ★ 496.00 |
| 52 Week Low | $15.07 | $1.18 |
| 52 Week High | $22.71 | $2.58 |
Technical Indicators
Market Signals| Indicator | CTO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 69.74 |
| Support Level | $21.22 | $1.31 |
| Resistance Level | $22.01 | N/A |
| Average True Range (ATR) | 0.32 | 0.22 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 55.17 | 88.66 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.